There is an Old Peter sellers Film, Being There, In it Sellers plays Chauncey Gardner, a simple fellow who is found in the House of a recently passed away Rich employer, he is the Gardner at the property and by a series of coincidences Gardner ends up as the advisor to the President of the USA.

WItchHunt #LabourAntiSemitism #McCarthyism New FIlm https://t.co/tuqPCQiWC6

— Wiki_Ballot (@wiki_ballot) November 27, 2019

 

Being There

Rand is also a confidant and advisor to the President of the United States, whom he introduces to “Chauncey.” In a discussion about the economy, Chance takes his cue from the words “stimulate growth” and talks about the changing seasons of the garden. The President misinterprets this as optimistic political advice and quotes “Chauncey Gardiner” in a speech. Chance now rises to national prominence, attends important dinners, develops a close connection with the Soviet ambassador, and appears on a television talk show during which his detailed advice about what a serious gardener should do is misunderstood as his opinion on what would be his presidential policy.

Though he has now risen to the top of Washington society, the Secret Service and some 16 other agencies are unable to find any background information on him. During this time Rand’s physician, Dr. Allenby, becomes increasingly suspicious that Chance is not a wise political expert and that the mystery of his identity may have a more mundane explanation. Dr. Allenby considers telling Rand this, but realizing how happy Chance is making him in his final days keeps him silent.

Jeremy Corbyn is a Keen Gardner and he too is perhaps part of a larger plan being hatched by the Global establishment. Are we to believe that Jeremy Corbyn is the Human equivalent of 9/11 defeating the most controlled and narrative-driven period of political manipulations for the past 100 years?

9/11 A Conspiracy Theory (Corbett Report) #GrubStreetJournal #Wiki_Ballot https://t.co/tT46PRhLHt

— Wiki_Ballot (@wiki_ballot) November 27, 2019

Two recent open goals have been presented to Mr Corbyns Labour Party, The Waspi’s and now the unredacted NHS negotiations wrapped up in the US Trade deal negotiations. The Establishment wants Mr Corbyns Labour to do well but not that well, after all, they have some re warmed Brino to serve up to the unsuspecting British electorate and Mr Johnson, BoJo the clown, is the Specially selected Bar Steward anointed with the task of forcing that tipple down the electorates Throat. Meanwhile to keep things plausibly close but not too close, Mr Farage will be enlightening the British Public Just enough on the Aspects of EU Military Union that it is planned will again keep the House of Commons as such composition that it will remain biddable to the establishments designs but not Honest in the sense of what is in the best interests of the British Public. Of course, the Establishments wish to saddle us with one of its Brightest and best In the One trick pony show of the NWO reality-based community chest, say a David Milliband, a Jeremy Hunt or a Chucka Ummana, all Rhodes Sholarshiped and Erasmus awarded up or all Allbright and beautiful like a Bill Clinton, an early model or a Jimmy Carter? Tony Blair/Cameron/Maywitch project, anyone? They have succeeded with this in Canada with Trudeau and France with Macron, what is it with french Speaking electorates and Election Rigging. It remains to be seen how the Establishment will seek to put one of their Show Ponies back into the Whitehouse, tune in for next years special instalment.

OFFICIAL SENSITIVE First UK… by Guido Fawkes on Scribd

OFFICIAL SENSITIVE Fourth U… by Guido Fawkes on Scribd

OFFICIAL SENSITIVE Fifth UK… by Guido Fawkes on Scribd

NHS

•   The query about 'health insurance' was likely a fishing expedition to check the tone of our
    response. We do not currently believe the US has a major offensive interest in this space –
    not through the SOE chapter at least. Our response dealt with this for now, but we will need
    to be able to go into more detail about the functioning of the NHS and our views on whether
    or not it is engaged in commercial activities, including through consultation with the Public
    Services team in TPD.




                                                                                               53

Administration may want a shift in some areas of policy here so they were unable to answer some of

    the questions we posed. It was nevertheless a very helpful exposition on the key areas we can expect
    the US to push in an FTA and for us to start to determine the areas where we may find ourselves in
    difficult territory. The impact of some patent issues raised on NHS access to generic drugs (i.e. cheaper
    drugs) will be a key consideration going forward.

SB (UK) explained that the consultations with the public on trade with the US, New Zealand,
Australia and potentially exploring CPTPP formally launched on July 20 and closed Oct 26.
Privately the UK has received 160,000 responses from US consultation. Less were bespoke
individual responses and many more were from campaigns which has themes that were expected
based on TTIP: NHS protection, high food standards, and ISDS challenging sovereignty. The UK
government will not response to every comment, but instead will publishing a government
response to concerns and opportunities including how the government will consider them in future
trade talks.

SB (UK) explained that the consultations with the public on trade with the US, New Zealand,
Australia and potentially exploring CPTPP formally launched on July 20 and closed Oct 26.
Privately the UK has received 160,000 responses from US consultation. Less were bespoke
individual responses and many more were from campaigns which has themes that were expected
based on TTIP: NHS protection, high food standards, and ISDS challenging sovereignty. The UK
government will not response to every comment, but instead will publishing a government

HEALTH

15.   DCMS highlighted that broadly, the US and the UK clearly have a lot of common interests in this area,
      and that this will be a fruitful area of future discussion. The US said that the most problematic area
      within the data localization issue is health information and the HIPAA (Health Insurance Portability and
      Accountability Act, 1996), which dictates that cross-border data flows are allowed as long as certain

harmonisation during EU Exit.

 The US view the introduction of warning labels as harmful rather than as a step to public health.

16. The UK (Surrey) asked how public health, and broader issues like sugar content, fat, anti-microbial
    resistance fit into the regulatory system. Callahan acknowledged that these are important global issues.
    Whilst they follow the guidance set by WHO, they are concerned that labelling food with high sugar
    content (as has been done with tobacco) is not particularly useful in changing consumer behaviour.

2. The US (Peterson) responded that there is data protection for big and small molecules. The US started
    with small molecule protection which is set as five years. The passage of the American Health Care Act

11. The UK (Whitehead) stated the EU is looking at the balance achieved by the existing SPC regime in the
    EU. The UK asked whether the US had done any research on the balance between health systems and
    rights holders?
12. The US (Peterson) stated that it believes there was some done in TPP and the US can look into this for
    the UK.

      burdens. However, Health and Safety and Environmental areas cannot be exempt. Different sectors

2. KT highlighted ‘significant’ private sector interest on both sides of the Atlantic in the Blue
   Economy [which – as part of the ‘clusters’ model – involves development of dynamic regional,
   national and international linkages between commercial, research and public-sector
   stakeholders to promote sustainable use of ocean resources for economic growth, improved
   livelihoods and jobs, and ocean ecosystem health]. While KT explained that the US does not

4. KT set out that cooperation would take place within the framework of the Galway Trilateral
   Context (i.e. in the context of the Galway Statement (2013) between the EU, Canada and the
   United States of America). Primary concerns under this agenda at present include:
       o The sustainable use of ocean resources in the North Atlantic, and understanding of
          current and future stressors on ocean health (e.g. business, tourism, etc.);

2. PK noted that smart fabrics are for an emerging priority for the US, and this is driving a lot of
   cluster work in certain areas (i.e. health, and general apparel). There is also a great deal of
   interest in drone-technology, with a lot of University-level activity and an inter-regional
   competition focussed on different aspects of drone use and different forms of drone-technology
   application (e.g. agriculture; how drones interact with local airspace). There may be good
   opportunities for collaborating on drone technology, although it is less certain where we might
   collaborate on the robotics side given this is not a Silicon Valley cluster focus.

4. KT sounded a cautionary note, underscoring public sensitivities over the perceived risks to
   livelihoods posed by these technologies. We may want to look at profiling transformative sectors
   that are perceived as having a less ambiguous socio-economic impact, such as e-health (where
   a lot of work is being done). While we accepted this risk, CS noted that there is operationally no
   reason that we should not invite the robotics cluster to participate at the April 2019 event; we can
   then decide on appropriate framing and messaging to ensure that this does not generate
   concerns over job-losses.

Emily Bleimund (EB – VC)                 Health and Human Services (HHS)

The US (Callahan) outlined that during the recent June VTC, discussion was focussed on APHIS.
The US stressed the need for a technical discussion to talk through specifics on animal health as
there are no problems on the plant health side.

Key Actions and Next Steps:

VEA
• The need for a regulator-to-regulator discussion on issues on the animal health side.
•   The UK will share a short form text, mindful of the US position.
•   The UK will let the US know why our regulators need specific parts of the VEA as on the US side
    trade would continue without it – the UK needs to establish why it would not from a UK regulatory
    perspective.
•   The US expressed a willingness to transition the agreement if we have a commitment to
    renegotiate in April 2019.

Daisy Ellis (DE)                               Medicines and Healthcare Products

Rachel Mumford (RM)                            Department for Health (DH)

Donald Beers (DB – VC)                         Health and Human Services (HHS)

Key Points to Note:
1. This session provided the UK with an opportunity to provide a comprehensive overview of our
   approach to patent policy and highlight how this is intricately linked to the UK health system. The
   UK provided a broad overview of how the UK patent system contributes to an innovative pharma
   sector and facilitates a balance between generics, innovators and the public whilst stressing the
   importance of this system for the health sector. A strategic approach combining five


                                                                                                  119

Report of Discussions and Outcome:
Introductions
1. MP (UK) introduced the day’s session, split into 5 UK mini-presentations and 1 US overview of
   their non-paper. The session with focus on patents with respect to pharmaceuticals and health,
   topics covered will be:
       o Overview of UK innovation and how the patent system works with respect to
           pharmaceuticals/health system
       o A UK patent system case study
       o USTR to present their non-paper
       o Data/market exclusivity rules in the UK
       o Supplementary Patent Certificates
       o An overview of the UK Patent Courts
                                                                                               120

3. AT (UK) presented the UK pharmaceutical sector and outlined why the UK patent regime was

     central to this industry. The pharmaceutical sector has an annual turnover of £48.2 billion, it
     employs over 100,000 people from 2,000 businesses, and it is closely integrated with the UK’s
     national health system. The UK sector has strong links with the international pharmaceutical
     sector. The strength of the UK science industry is critical to the strength of the pharma sector.
     These companies are looking to protect their investment in R&D and therefore have a great
     interest in the UK patent system. The UK government is one of highest spenders on the
     innovative pharmaceuticals industry, second only to the US on government expenditure in this
     area. When looking at the life sciences strategy in the wider industrial strategy, R&D is vital,
     therefore the patent system is key for maintaining and enhancing UK R&D and its foothold in the
     larger global R&D industry.

5. A fundamental principle that runs through the UK IP system is the balance of providing exclusive

     rights to encourage investment and innovation, whilst recognising there is a health need for these
     innovative products and therefore a need to ensure that they are appropriately available. The UK
     takes a balanced approach to our IP regime, considering the interests of generics, public and
     innovators.

80. Publication of marketing approval - Marketing authorities are not involved in the process to
    determine what (if any) infringement is occurring when a generic applies for authorisation. The
    market authorisation process is purely scientific, concerning the clinical, safety and health
    implications of the product. Therefore, a generic can get market authorisation even if litigation
    has commenced. MHRA publishes all products that have received marketing approval monthly.
    Innovators can see any generics who have gained marketing approval and take legal action if
    required.

•   We have reached a point (for Patents in Pharmaceuticals/Health) where beyond specific policy
    details in niche areas, we are awaiting the clearance to negotiate and exchange text to really
    take significant further steps. There is however significant scope to discuss patents in other areas
    at future sessions, in particular: Technology and Agriculture/Chemicals.

32. Nursing was the other profession that the US was interested in. Nursing in the US was very closely co-
    ordinated with Canada and Ireland. The relationship with Canada was particularly close and Canada had
    adopted the US exam. A compact between 25-30 states meant that nurses were able to move between
    those states. The US were interested to know if it would be really problematic for the UK to act in this
    area – they were sensitive to the particular sensitivities with the health sector in the UK.

Anne Snyder                                       US Department of Health and Human Services

  •    USTR probed UK position on our 'health insurance' system

8. USTR asked about the UK portfolio of SOEs (understood that it was small) and if the

      UK had concerns about their “health insurance system”

DIT: Wouldn’t want to go down avenue of talking about specific entities but the UK has an

       advanced competition law regime and strong corporate governance rules, and we believe
       we are compliant with international best practice. Wouldn’t want to discuss particular health
       care entities at this time, you’ll be aware of certain statements saying we need to protect
       our needs; this would be something to discuss further down the line when we come to
       consider what entities would count as 'enterprises'.

•   The query about 'health insurance' was likely a fishing expedition to check the tone of our
    response. We do not currently believe the US has a major offensive interest in this space –
    not through the SOE chapter at least. Our response dealt with this for now, but we will need
    to be able to go into more detail about the functioning of the NHS and our views on whether
    or not it is engaged in commercial activities, including through consultation with the Public

15.   DCMS highlighted that broadly, the US and the UK clearly have a lot of common interests in this area,
      and that this will be a fruitful area of future discussion. The US said that the most problematic area
      within the data localization issue is health information and the HIPAA (Health Insurance Portability and
      Accountability Act, 1996)

harmonisation during EU Exit.

 The US view the introduction of warning labels as harmful rather than as a step to public health.

16. The UK (Surrey) asked how public health, and broader issues like sugar content, fat, anti-microbial
    resistance fit into the regulatory system. Callahan acknowledged that these are important global issues.
    Whilst they follow the guidance set by WHO, they are concerned that labelling food with high sugar
    content (as has been done with tobacco) is not particularly useful in changing consumer behaviour.

Michael Moore #MAGA Speech Joe Blo Biggest FU in history Speech https://t.co/oeoSPnFxv1 #BitChute

— Wiki_Ballot (@wiki_ballot) November 27, 2019

In this other Sellers performance, we see Jean Claude junker and Luxembourg Taking on the USA?

David James, Baron James of Blackheath #EUMilitaryUnification @ukcolumn https://t.co/pttrfGCjtv #BitChute

— Wiki_Ballot (@wiki_ballot) November 27, 2019